Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Cutting Cost Of R&D Under Efficiency Program; Output To Double

Executive Summary

Pfizer hopes to double output from its research and development operations while holding R&D costs in line with historic increases, CEO Hank McKinnell told investors July 20

You may also be interested in...



Pfizer Sets Sights On Becoming Top Five Biologics Player By 2010

Pfizer is emphasizing a diversified approach, focusing on both small molecules and biotech products, as it attempts to regain investor confidence in the company's growth potential

Pfizer Sets Sights On Becoming Top Five Biologics Player By 2010

Pfizer is emphasizing a diversified approach, focusing on both small molecules and biotech products, as it attempts to regain investor confidence in the company's growth potential

Pfizer’s Product Parachute? Firm Could See Rally Around New Approvals

Related Content

Topics

UsernamePublicRestriction

Register

PS046125

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel